Rosales Minori 4
4 · Sesen Bio, Inc. · Filed Jan 26, 2022
Insider Transaction Report
Form 4
Sesen Bio, Inc.SESN
Rosales Minori
Chief Development Officer
Transactions
- Award
Common Stock
2022-01-24+623,000→ 623,000 totalExercise: $0.73Exp: 2032-01-24→ Common Stock (623,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to such option shall vest on the first anniversary of the date of grant of the option and an additional 6.25% of the shares underlying the option shall vest at the end of each successive three-month period thereafter until the fourth anniversary of the date of grant of the option. Based on market analysis by Radford of public, pre-commercial and commercial biopharmaceutical companies, the compensation committee of Sesen Bio, Inc ("the Company"), recommended to the Company's board of directors, and the board of directors approved, the grant to the reporting person.